相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
David J. Pinato et al.
HEPATOLOGY (2021)
Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Tom van den Ende et al.
CLINICAL CANCER RESEARCH (2021)
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
Chengqiang Li et al.
EUROPEAN JOURNAL OF CANCER (2021)
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma A Randomized Clinical Trial
Hao Wang et al.
JAMA SURGERY (2021)
RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
Lin Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
A new Standard is emerging: PD-1 Maintenance Therapy after neoadjuvant Radiochemotherapy and curative Resection for Esophageal and AEG Carcinomas (CheckMate 577)
Robert Michael Hermann et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2021)
Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer
Kohei Yamashita et al.
GASTRIC CANCER (2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
P. Schmid et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Hai-Bo Sun et al.
BMC CANCER (2020)
Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma
Yongping Cui et al.
CELL RESEARCH (2020)
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
Catherine A. Shu et al.
LANCET ONCOLOGY (2020)
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Raghav Sundar et al.
FRONTIERS IN ONCOLOGY (2020)
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2020)
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
Si-Yang Liu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
Afaf Abed et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Epidemiology of esophageal cancer: update in global trends, etiology and risk factors
Dustin J. Uhlenhopp et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.
Tom van den Ende et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A good start of immunotherapy in esophageal cancer
Qian Zhao et al.
CANCER MEDICINE (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
The immune landscape of esophageal cancer
Tu-Xiong Huang et al.
CANCER COMMUNICATIONS (2019)
STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery
Riaz Agha et al.
INTERNATIONAL JOURNAL OF SURGERY (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Epidemiology of Esophageal Squamous Cell Carcinoma
Christian C. Abnet et al.
GASTROENTEROLOGY (2018)
Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer
Keiji Hayata et al.
ANTICANCER RESEARCH (2018)
Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).
Karina Kulangara et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
Hong Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Gideon M. Blumenthal et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
Mingqiu Chen et al.
RADIATION ONCOLOGY (2018)
Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer
Tamer Soror et al.
JOURNAL OF THORACIC DISEASE (2018)
Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
Yuqin Song et al.
BLOOD (2018)
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
David Cunningham et al.
LANCET ONCOLOGY (2017)
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
Derek Alderson et al.
LANCET ONCOLOGY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Overview of esophageal cancer
Ghulam Abbas et al.
ANNALS OF CARDIOTHORACIC SURGERY (2017)
Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer
Linda E. Kelemen et al.
GYNECOLOGIC ONCOLOGY (2016)
Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
Hai-ying Wang et al.
ONCOTARGETS AND THERAPY (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Prognostic Significance of Positive Circumferential Resection Margin in Esophageal Cancer: A Systematic Review and Meta-Analysis
Jie Wu et al.
ANNALS OF THORACIC SURGERY (2014)
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
Ren-Wen Huang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas et al.
LANCET ONCOLOGY (2010)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K Becker et al.
CANCER (2003)
分享论文
